Cutler Group LP Solid Biosciences Inc. Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Oct 26, 2021	BUY	$2.38 - $3.77 $20,230 - $32,045	8,500 Added 850.0%	9,500 $2,000
Q2 2020 Jul 22, 2020	SELL	$2.1 - $3.42 $210 - $342	-100 Reduced 9.09%	1,000 $0
Q1 2020 May 07, 2020	BUY	$2.31 - $4.43 $2,310 - $4,430	1,000 Added 1000.0%	1,100 $0
Q4 2019 Feb 06, 2020	SELL	$2.82 - $12.9 $3,102 - $14,190	-1,100 Reduced 91.67%	100 $0
Q3 2019 Oct 28, 2019	BUY	$4.33 - $11.64 $4,330 - $11,640	1,000 Added 500.0%	1,200 $3,000
Q2 2019 Aug 09, 2019	SELL	$4.6 - $10.13 $7,359 - $16,208	-1,600 Reduced 88.89%	200 $0
Q1 2019 May 10, 2019	BUY	$7.19 - $32.37 $5,033 - $22,659	700 Added 63.64%	1,800 $1,000
Q4 2018 Feb 05, 2019	BUY	$21.32 - $46.34 $23,452 - $50,974	1,100 New	1,100 $0

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $53.2M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.